Tekcapital : Reporting Document

BUILDING VALUABLE

COMPANIES

WITH UNIVERSITY

DISCOVERIES

INVESTOR PRESENTATION

July 2022

AIM:TEK, OTCQB: TEKCF © 2022 Tekcapital plc Tekcapital.com

IMPORTANT NOTICE

By accepting this document, and in consideration for it being made available to such recipient, each recipient agrees to keep strictly confidential the information contained in it and any information otherwise made available by Tekcapital Plc (the "Company"), whether orally or in writing. In the case of a corporate recipient, this presentation may only be disclosed to such of its directors, officers or employees who are required to review it for the purpose of deciding whether to make an investment in the Company. This

document has been provided to each recipient at their request, solely for their information, and may not be

reproduced, copied, published, distributed or circulated, to any third party, in whole or in part, or published in whole or in part for any purpose, without the express prior consent of the Company. The purpose of this document is solely to provide information to persons who have expressed an interest in investigating the possibility of investing in the Company.

The information contained in this confidential document (the "Presentation") has been prepared and distributed by the Company. It has not been fully verified and is subject to material updating, completion, revision, verification and further amendment. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This Presentation does not constitute, and the Company is not making, an offer of transferable securities to the public within the meaning of sections 85B and 102B of FSMA and it is being delivered for information purposes only to a very limited number of persons and companies who are 'qualified investors' within the meaning of section 86(7) of FSMA purchasing as principal or in circumstances under section 86(2) of FSMA, as well as persons who have professional experience in matters relating to investments and who fall

within the category of persons set out in Article 19 of the Financial Services and Markets Act 2000 (Financial

Promotion) Order 2005 (the "Order") or are high net worth companies within the meaning set out in Article

49 of the Order or are certified sophisticated investors within the meaning set out in Article 50 of the Order or are a "professional client" or an "eligible counterparty" within the meaning of Article 4 (1)(II) and 24(2), (3) and (4), respectively, of Markets in Financial Instruments Directive (Directive 2004/39/EC) ("MiFID") as MiFID is implemented into national law of the relevant EEA state or are otherwise permitted to receive it (together, the "Relevant Persons"). This Presentation is directed only at Relevant Persons and must not be acted on or relied upon by persons who are not Relevant Persons. Any other person who receives this Presentation should not rely or act upon it. By accepting this Presentation and not immediately returning it, the recipient is deemed to represent and warrant that: (i) they are a person who falls within the above description of persons entitled to receive the Presentation; (ii) they have read, agree and will comply with the contents of this notice; and (iii) they will use the information in this document solely for evaluating your possible interest in acquiring securities of the Company.

The securities mentioned herein have not been and will not be, registered under the U.S. Securities Act of

1933, as amended (the "Securities Act"), or under any U.S. State securities laws, and may not be offered or

sold in the United States of America or its territories or possessions (the "United States") unless they are registered under the Securities Act or pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. Neither this Presentation nor any copy of it may be taken or transmitted into the United States, or distributed, directly or indirectly, in the United States, or to any "US person" as defined in Regulation S under the Securities Act of 1933, including US resident corporations or other entities organised under the laws of the United States or any state thereof or non-U.S. branches or agencies of such corporations or entities. This Presentation is not being made available to persons in Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or any other jurisdiction in which it may be unlawful to do so and it should not be delivered or distributed, directly or indirectly, into or within any such jurisdictions.

The information described in this Presentation may contain certain material information that is confidential, price-sensitive and which has not been publically disclosed. By your receipt of this Presentation you recognise and accept that some or all of the information in this Presentation may be "inside information" as

defined in Article 7 of the Market Abuse Regulation EU 596/2014 ("MAR"), Section 118C of the FSMA, section

56 of the Criminal Justice Act 1993 ("CJA") and the Disclosure and Transparency Rules ("DTRs") and constitutes a "market sounding" for the purpose of Article 11 of MAR. You recognise and accept that such information is being provided to you by the Company pursuant to Article 11 of MAR and DTR 2.5.7G(2)(b) and you confirm, warrant and undertake that you will not: (i) deal in securities that are price-affected securities (as defined in the CJA) in relation to the inside information, encourage another person to deal in price-affected securities or disclose the information except as permitted by the CJA or MAR or before the inside information is made public; (ii) or cancel or amend an order which has already been placed concerning a financial instrument (as defined in MAR) to which the inside information relates; (iii) deal or

attempt to deal in a qualifying investment or related investment (as defined in MAR) on the basis of the inside information; (iv) disclose the inside information to another person other than in the proper course of the exercise of your employment, profession or duties; or (v) engage in behaviour based on any inside information which might amount to market abuse or market manipulation for the purposes of MAR. Recipients should take their own legal advice on the obligation to which they will be subject and the

application of MAR and in particular make their own assessment of whether they are in possession of inside

information and when such information ceases to be inside information.

Prospective investors must rely on their own examination of the legal, taxation, financial and other consequences of an investment in the Company, including the merits of investing and the risks involved. Prospective investors should not treat the contents of this Presentation as advice relating to legal, taxation or investment matters and are advised to consult their own professional advisers concerning any acquisition of shares in the Company.

Certain of the information contained in this Presentation has been obtained from published sources prepared by other parties. Certain other information has been extracted from unpublished sources prepared by other parties which have been made available to the Company. The Company has not carried out an independent investigation to verify the accuracy and completeness of such third party information. No responsibility is accepted by the Company or any of its directors, officers, employees or agents for the accuracy or completeness of such information.

All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation. In addition, this Presentation contains certain "forward-looking statements", including but not limited to, the statements regarding the Company's overall objectives and strategic plans, timetables and capital expenditures. Forward-looking statements express, as at the date of this Presentation, the Company's plans, estimates, forecasts, projections, opinions, expectations or beliefs as to future events, results or performance. Forward-looking statements involve a number of risks and uncertainties, many of which are beyond the Company's control, and there can be no assurance that such statements will prove to be accurate. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its directors, officers, employees or agents in respect thereof. The Company does not undertake to update any forward-looking statement or other information that is contained in this Presentation. Neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any

liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect

of, the accuracy or completeness of the information contained in this Presentation or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of contract, commitment or recommendation on the part of the Company or the directors of the Company to proceed with any transaction or accept any offer and the right is reserved to terminate any discussions or negotiations with any prospective investors. The Company reserves the right without any notice or liability to the recipient of this Presentation or its advisers to: (i) change any of the procedures, timetable or requirements or terminate negotiations at any time prior to the signing of any binding agreement with investors; (ii) provide different information or access to information to different persons; (iii) agree variations to the property, rights and liabilities comprised in the Company; and (iv) negotiate at the same time with more than one person. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. This Presentation

should not be considered a recommendation by the Company or any of its affiliates in relation to any

prospective acquisition of shares in the Company. Please be aware that the Company's net asset value and financial results will fluctuate due to a wide variety of Company specific and macro-economic conditions.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or any of its affiliates, any of its directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted for any such information or opinions or for any errors or omissions.

Further, due to the Covid 19 pandemic, Company results, and net assets may be negatively impacted.

TRANSFORMING UNIVERSITY DISCOVERIES

INTO VALUABLE NEW PRODUCTS

Building portfolio	Providing	Multi-year track
companies with	technology	record of significant
university technology	transfer services	growth of net assets
coupled with star power	for 250+ leading	and returns on
management	universities	invested capital

"In addition to a growing portfolio of university IP investments, Tekcapital helps research institutions and businesses develop disruptive technologies and expand their portfolios of intellectual capital." -Julian Mitchell

3

3

2021 FINANCIAL RESULTS

OBJECTIVE

Grow our Net Assets by building portfolio companies around compelling innovations that can improve people's lives.

PERFORMANCE

Net assets increased 108% to $68.1m (30 Nov 2020: $32.7m)

NAV per share $0.48 (30 Nov 2020: $0.35)

Total revenue $29.2m (30 Nov 2020: $9.9m)

-Increase of $28.7m in fair value of investments (30 Nov 2020: $8.7m)

-Revenue from services $0.8m (30 Nov 2020: $0.9m)

Profit after tax $26.4m (30 Nov 2020: $7.7m)

Diluted EPS $0.21 (30 Nov 2020: $0.09)

4

4

2021 FINANCIAL RESULTS

5

5